Androgen receptor mediates the expression of UDP‐glucuronosyltransferase 2 B15 and B17 genes
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Enhanced androgen receptor (AR) activity by increased testosterone availability may play important roles in prostate cancer progressing to castration resistant state. Comparison of expression profiles in androgen dependent and independent prostate tumors demonstrated a marked increase of the expression of UDP‐glucuronosyltransferase 2B15 (UGT2B15), an androgen catabolic enzyme. We investigated mechanisms controlling the differential expression of UGT2B15 and B17 in response to androgen treatments. METHODS: Gene expression was determined by RT‐PCR. The association of AR with UGT2B15/B17 genes was determined by Chromatin immuno‐precipitation (CHIP). RNA interference was used to knock‐down gene expression. RESULTS: UGT2B15 and B17 genes were not expressed in AR negative prostate cancer cell lines, PC3 and DU145, while they were expressed in AR positive cell lines, LNCaP, LNCaP‐abl (an androgen independent LNCaP sub‐line), and VCaP. The expression levels of UGT2B15/B17 were up‐regulated in LNCaP‐abl comparing to those in LNCaP. These results suggest the requirement of AR for the expression of UGT2B15/B17. Treatment with DHT down‐regulated the expression of UGT2B15/B17 in LNCaP in a time and dose dependent manner and this down‐regulation was competitively antagonized by flutamide and bicalutimide, suggesting a pathway mediated by AR. Further CHIP experiments demonstrated the direct interaction of AR with the promoter regions of UGT2B15/B17 genes. Knocking down AR expression in LNCaP significantly reduced the expression of UGT2B15/B17 and completely inhibited the DHT‐induced down‐regulation of UGT2B15/B17 genes. CONCLUSIONS: We demonstrated that UGT2B15 and B17 are primary androgen‐regulated genes and AR is required for both their basal expression and their androgen‐regulated expression. Prostate 68:839–848, 2008. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Self-citationThe Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675 · cited 1×
“The increased expression of UGT2B15 and B17, presumably facilitating androgen catabolism, in CRPC is apparently paradoxical to the relatively high levels of testosterone observed in androgen-independent prostate biopsy samples [6,31,32].”
BackgroundHolzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577
Androgen receptor as a target in androgen-independent prostate cancer
Balk, S. P. (2002) · Urology · doi:10.1016/s0090-4295(02)01593-5 · Cited by 264
Self-citationChouinard, S., Barbier, O., & Bélanger, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703370200 · Cited by 109
Geller, J., Albert, J. D., Nachtsheim, D. A., & Loza, D. (1984) · Journal of Urology · doi:10.1016/s0022-5347(17)49829-6 · Cited by 98 · cited 1×
“The increased expression of UGT2B15 and B17, presumably facilitating androgen catabolism, in CRPC is apparently paradoxical to the relatively high levels of testosterone observed in androgen-independent prostate biopsy samples [6,31,32].”
Background
Cited by
The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms
Meech, R., Hu, D. G., McKinnon, R. A., Mubarokah, S. N., Haines, A. Z., Nair, P. C., Rowland, A., & Mackenzie, P. I. (2019) · Physiological Reviews · doi:10.1152/physrev.00058.2017 · Cited by 368
Androgen‐responsive long noncoding RNA CTBP1‐AS promotes prostate cancer
Takayama, K., Horie‐Inoue, K., Katayama, S., Suzuki, T., Tsutsumi, S., Ikeda, K., Urano, T., Fujimura, T., Takagi, K., Takahashi, S., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.99 · Cited by 278
Pretorius, E., Africander, D. J., Vlok, M., Perkins, M. S., Quanson, J., & Storbeck, K.-H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159867 · Cited by 148
Li, C. Y., Basit, A., Gupta, A., Gáborik, Z., Kis, E., & Prasad, B. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.03.027 · Cited by 73
“Especially UGT2B17 is very selective and efficient towards testosterone, and it is highly expressed in intestine with increasing expression along the intestinal tract [11].”
BackgroundGauthier-Landry, L., Bélanger, A., & Barbier, O. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.05.009 · Cited by 62
Metadata
- Authors
- Bao, B., Chuang, B., Wang, Q., Sartor, O., Balk, S. P., Brown, M., Kantoff, P. W., & Lee, G. M.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2008-02-26
- Volume
- 68
- Issue
- 8
- Pages
- 839-848
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2047893575
- Cited by
- 79
- References
- 9
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.